Literature DB >> 28446516

Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease.

Joshua W Knowles1, William B Howard2, Lala Karayan2, Seth J Baum2, Katherine A Wilemon2, Christie M Ballantyne2, Kelly D Myers2.   

Abstract

Entities:  

Keywords:  PCSK9 inhibitor, human; atherosclerosis; familial hypercholesterolemia

Mesh：

Substances：

Year:  2017        PMID： 28446516     DOI： 10.1161/CIRCULATIONAHA.117.027705

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  10 in total

1.  Application of PCSK9 Inhibitors in Practice.

Authors:  Tina M Kaufman; Bruce A Warden; Jessica Minnier; Joshua R Miles; P Barton Duell; Jonathan Q Purnell; Cezary Wojcik; Sergio Fazio; Michael D Shapiro
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

2.  Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.

Authors:  Ann Marie Navar; Benjamin Taylor; Hillary Mulder; Eugene Fievitz; Keri L Monda; Anna Fievitz; Juan F Maya; J Antonio G López; Eric D Peterson
Journal:  JAMA Cardiol       Date:  2017-11-01       Impact factor: 14.676

Review 3.  Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.

Authors:  Anandita Agarwala; Renato Quispe; Anne C Goldberg; Erin D Michos
Journal:  Drug Des Devel Ther       Date:  2021-05-10       Impact factor: 4.162

Review 4.  PCSK9 inhibitor valuation: A science-based review of the two recent models.

Authors:  Seth J Baum; Christopher P Cannon
Journal:  Clin Cardiol       Date:  2018-03-07       Impact factor: 2.882

5.  PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.

Authors:  Alanna M Chamberlain; Yan Gong; Kathryn McAuliffe Shaw; Jiang Bian; Wen-Liang Song; MacRae F Linton; Vivian Fonseca; Eboni Price-Haywood; Emily Guhl; Jordan B King; Rashmee U Shah; Jon Puro; Elizabeth Shenkman; Pamala A Pawloski; Karen L Margolis; Adrian F Hernandez; Rhonda M Cooper-DeHoff
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

6.  Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease: Insights From the Oncology Drug Development Experience.

Authors:  Aarif Y Khakoo; Nicole R Yurgin; Paul R Eisenberg; Gregg C Fonarow
Journal:  JACC Basic Transl Sci       Date:  2019-04-29

Review 7.  Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.

Authors:  Leo E Akioyamen; Jacques Genest; Shubham D Shan; Rachel L Reel; Jordan M Albaum; Anna Chu; Jack V Tu
Journal:  BMJ Open       Date:  2017-09-01       Impact factor: 2.692

8.  Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology.

Authors:  Amit Khera; Seth J Baum; Ty J Gluckman; Martha Gulati; Seth S Martin; Erin D Michos; Ann Marie Navar; Pam R Taub; Peter P Toth; Salim S Virani; Nathan D Wong; Michael D Shapiro
Journal:  Am J Prev Cardiol       Date:  2020-05-01

9.  PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks.

Authors:  Tim Hollstein; Ursula Kassner; Thomas Grenkowitz; Friederike Schumann; Thomas Bobbert; Elisabeth Steinhagen-Thiessen
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

10.  Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice.

Authors:  Bruce A Warden; Jonathan Q Purnell; P Barton Duell; Courtney Craigan; Diane Osborn; Emily Cabot; Sergio Fazio
Journal:  Am J Prev Cardiol       Date:  2021-01-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.